Platelet Activation Markers in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.

Szczegóły
Abstrakt

Tytuł:: Platelet Activation Markers in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.
Autorzy:: Awad A; Pediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Elnemr S; Pediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Hodeib H; Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
El Amrousy D; Pediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt. .
Źródło:: Pediatric cardiology [Pediatr Cardiol] 2022 Aug; Vol. 43 (6), pp. 1264-1270. Date of Electronic Publication: 2022 Mar 02.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: New York Ny : Springer Verlag
Original Publication: [New York, Springer-Verlag]
MeSH Terms:: Heart Defects, Congenital*/complications
Pulmonary Arterial Hypertension*
Biomarkers ; Blood Platelets ; Child ; Familial Primary Pulmonary Hypertension/complications ; Humans ; Mean Platelet Volume ; Platelet Activation ; Platelet Count ; Prospective Studies
References:: Eur Heart J. 1993 Feb;14(2):205-12. (PMID: 8449196)
Eur Heart J. 2016 Jan 1;37(1):67-119. (PMID: 26320113)
Am J Sports Med. 2011 Apr;39(4):729-34. (PMID: 21398575)
Cardiol Young. 2018 Sep;28(9):1163-1168. (PMID: 29950194)
Eur Heart J. 2009 Oct;30(20):2493-537. (PMID: 19713419)
Platelets. 2014;25(2):81-5. (PMID: 23469987)
Circulation. 2015 Nov 24;132(21):2037-99. (PMID: 26534956)
Circulation. 2000 Nov 28;102(22):2720-5. (PMID: 11094038)
Cardiol Young. 2020 Apr;30(4):533-538. (PMID: 32228739)
Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E171-4. (PMID: 21406414)
Pediatr Cardiol. 2013 Apr;34(4):1013-6. (PMID: 23254645)
Heart Lung Circ. 2015 Jun;24(6):566-72. (PMID: 25573235)
Isr Med Assoc J. 2009 Jun;11(6):376-9. (PMID: 19697592)
J Am Heart Assoc. 2014 Aug 21;3(4):. (PMID: 25146706)
Thromb Res. 2010 Oct;126(4):280-2. (PMID: 20673969)
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):40S-47S. (PMID: 15194177)
Acta Cardiol. 2014 Apr;69(2):161-6. (PMID: 24783467)
Circulation. 2010 Jul 13;122(2):164-72. (PMID: 20585012)
Eur J Pediatr. 2021 Sep;180(9):2889-2895. (PMID: 33813676)
Congenit Heart Dis. 2018 Jul;13(4):506-511. (PMID: 30019380)
Eur Heart J. 2001 Sep;22(17):1561-71. (PMID: 11492985)
Circulation. 2011 Mar 1;123(8):841-9. (PMID: 21321151)
Cardiol Young. 2015 Dec;25(8):1473-81. (PMID: 26675593)
J Am Soc Echocardiogr. 2013 May;26(5):457-63. (PMID: 23510536)
Int J Cardiol. 2011 Feb 17;147(1):4-12. (PMID: 20692712)
Platelets. 2002 Aug-Sep;13(5-6):301-6. (PMID: 12189016)
Nat Rev Cardiol. 2011 Jun 21;8(8):443-55. (PMID: 21691314)
Ann Med. 2004;36(7):552-7. (PMID: 15513305)
Circulation. 2012 Jan 3;125(1):113-22. (PMID: 22086881)
Contributed Indexing:: Keywords: Congenital heart disease; Platelet activation markers; Predictive markers; Prognosis; Pulmonary arterial hypertension
Substance Nomenclature:: 0 (Biomarkers)
Entry Date(s):: Date Created: 20220302 Date Completed: 20220720 Latest Revision: 20220721
Update Code:: 20240104
PubMed Central ID:: PMC9293825
DOI:: 10.1007/s00246-022-02847-7
PMID:: 35234994
: Czasopismo naukowe

Full Text Finder

The study aimed to evaluate mean platelet volume (MPV), platelet distribution width (PDW), and platecrit in children with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), to assess the predictive value of these platelet activation markers for adverse outcomes, and to correlate their levels with various data in these patients. This prospective cohort study included 60 children with PAH-CHD as group I and 60 children with CHD and no PAH as group II. Another 60 healthy children of matched age and sex served as the control group. All included children were evaluated by echocardiography. MPV, PDW, and platecrit were also measured using an automated blood counter. All patients were followed up for death or readmission for 6 months. MPV, PDW, and platecrit were significantly higher in group I compared to group II and the control group and they correlated well with increasing severity of PAH. MPV, PDW, and platecrit positively correlated with right ventricular diameter and mean pulmonary artery pressure, however they correlated negatively with right ventricular systolic and diastolic function. The best cut-off of platelet activation markers levels to predict poor prognosis in group I was > 11.2 FL with 75% sensitivity and 96.6% specificity for MPV, > 12.7 FL with 75% sensitivity and 61.5% specificity for PDW, and > 0.505% with 75% sensitivity and 93.2% specificity for platecrit. MPV, PDW, and platecrit were elevated in children with PAH-CHD and found to be good predictive markers for poor prognosis in these children.
(© 2022. The Author(s).)

Informacja